Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

Open access
Furusato, B, Tan, S-H, Young, D, Dobi, A, Sun, C, Mohamed, A A, Thangapazham, R, Chen, Y, McMaster, G, Sreenath, T, Petrovics, G, McLeod, D G, Srivastava, S, Sesterhenn, I A · 2010 · Prostate Cancer and Prostatic Diseases

Abstract

Gene fusions prevalent in prostate cancer (CaP) lead to the elevated expression of the ERG proto-oncogene. ERG activation present in 50-70% of prostate tumors underscores one of the most common oncogenic alterations in CaP. Despite numerous reports of gene fusions and mRNA expression, ERG oncoprotein status in CaP still remains to be defined. Furthermore, development of ERG protein-based assays may provide a new dimension to evaluation of gene fusions involving diverse androgen-regulated promoters and the ERG protein-coding sequence. Through exhaustive evaluations of 132 whole-mount prostates (261 tumor foci and over 200 000 benign glands) for the ERG oncoprotein nuclear expression, we demonstrated 99.9% specificity for detecting prostate tumor cells using a highly specific anti-ERG monoclonal antibody. The ERG oncoprotein expression correlated well with fusion transcript or gene fusion in randomly selected specimens. Strong concordance of ERG-positive foci of prostatic intraepithelial neoplasia (PIN) with ERG-positive carcinoma (82 out of 85 sections with PIN, 96.5%) affirms the biological role of ERG in clonal selection of prostate tumors in 65% (86 out of 132) of patients. Conversely, ERG negative PINs were associated with ERG-negative carcinoma. Taken together, the homogeneous and strong ERG expression detected in individual tumors establishes the potential for ERG oncoprotein-based stratification of CaP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/pcan.2010.23

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 236

Metadata

Authors
Furusato, B., Tan, S.-H., Young, D., Dobi, A., Sun, C., Mohamed, A. A., Thangapazham, R., Chen, Y., McMaster, G., Sreenath, T., Petrovics, G., McLeod, D. G., Srivastava, S., & Sesterhenn, I. A.
Venue
Prostate Cancer and Prostatic Diseases
Published
2010-06-29
Volume
13
Issue
3
Pages
228-237
ISSN
  • 1365-7852 (ISSN-L)
  • 1476-5608
OpenAlex
W2027845674
Cited by
236
References
2
FWCI
22.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. https://app.cochat.ai/papers/10.1038/pcan.2010.23
The paper
Furusato, B., Tan, S.-H., Young, D., Dobi, A., Sun, C., Mohamed, A. A., Thangapazham, R., Chen, Y., McMaster, G., Sreenath, T., Petrovics, G., McLeod, D. G., Srivastava, S., & Sesterhenn, I. A. (2010). ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/pcan.2010.23

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.